Quick Hits: Heartburn Drugs and Stroke Risk & FDA Official Stands by Controversial Drug Approval

Quick Hits: Transvaginal Mesh Pulled, New Weight Loss Drug & More

Taking common heartburn medications, such as Prilosec and Nexium, may boost your risk for a stroke. The drugs, known as PPIs (proton pump inhibitors), have been associated with vascular issues such as heart attacks, kidney disease and dementia. Based on the medical records of more than 244,000 Danish patients who had received an endoscopy, those who were taking a PPI had a 21% higher overall stroke risk, researchers said in a presentation at the American Heart Association’s annual meeting this week. The greater the dose of a PPI taken, the higher the stroke risk, they added, noting those who took the lowest doses of the antacids had only a slight or no increased risk. There was no higher risk with H2 blockers, another class of acid-reducing drugs that includes Pepcid and Zantac. Posted November 15, 2016. Via American Heart Association.

A top FDA official is defending the agency’s recent decision to approve a controversial drug even though the principal study included just 12 subjects, no placebo arm and questionable efficacy. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, told the Boston Globe that she is “very comfortable” with the decision to approve Exondys 51, the first drug to treat Duchenne muscular dystrophy. Although the FDA commissioner can make the final decision on a drug’s approval, it is widely understood that Woodcock’s recommendation to approve was accepted by the head of the agency. However, Woodcock admitted that the clinical study conducted by Sarepta, the developer of Exondys 51, “left so many questions.” But she noted, “You can have a pretty bad development program, and if you cross the finish line we might approve it anyway.” Woodcock added that input from patients also figures in the FDA’s decisions, calling them “experts in their diseases.” Posted November 16, 2016. Via Boston Globe.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

Flouride, PPIs, Breast Density and Prostate Cancer

Flouride, PPIs, Breast Density and Prostate Cancer

Startling news about fluoride, a study encourages more limites use of PPIs, does knowing the density of your breasts matter, and vegetables aren’t helpful in warding off prostate cancer (darn).  Be Well.  Fluoride and Pregnancy The medical community was shocked at the conclusions of two new studies on fluoride’s effect…

  • Advertisement